Lung Cancer: Targeted Therapy in 2025

Current Oncology, Journal Year: 2025, Volume and Issue: 32(3), P. 146 - 146

Published: March 2, 2025

Lung cancer treatment has changed in the last twenty years since discovery of EGFR mutations. In this article, we will review current state art for non-small cell lung (NSCLC) actionable genomic alterations (AGA). AGAs are mostly found adenocarcinomas, a subtype cancers. We focus on mutations, ALK fusions, ROS1 BRAF V600E MET exon 14-skipping RET KRAS G12C ERBB2 mutations (also called HER2 mutations), and NTRK fusions. also touch key toxicities associated with these medications. Treatments available metastatic stage, but discuss adjuvant therapy as well stage III post-chemoradiotherapy cancer.

Language: Английский

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

BMC Pulmonary Medicine, Journal Year: 2025, Volume and Issue: 25(1)

Published: Feb. 6, 2025

While clinical trials have demonstrated enduring responses to amivantamab among advanced non-small cell lung cancer (NSCLC) patients bearing EGFR exon 20 insertion mutations, the associated toxicity profile in real-world scenarios remains elusive. This pharmacovigilance study analyzed data from FDA Adverse Event Reporting System (FAERS) investigate adverse events with over period September 2021 December 2023. A comprehensive disproportionality analysis was performed, employing reporting odds ratio (ROR), proportional (PRR), Empirical Bayes Geometric Mean (EBGM), and Bayesian confidence propagation neural network calculate information components (ICs), identify statistically significant events. proportion of (AEs) attributable injury, poisoning, procedural complications, cutaneous disorders, respiratory ailments, infections, as well vascular lymphatic system disturbances. There were noteworthy incidences AEs including infusion-related reactions, rash, dyspnea, pneumonitis, paronychia, pulmonary embolism, thrombocytopenia, nausea, acneiform dermatitis, deep vein thrombosis, febrile neutropenia, peripheral edema, hypokalemia, neutropenia. Furthermore, majority occurred within first month following initiation treatment, accounting for 51.74% cases. The reversibility amivantamab-related toxicities suggests its promising utility mutations NSCLC.

Language: Английский

Trends in Overall Survival in Lung Adenocarcinoma with EFGR Mutation, KRAS Mutation, or No Mutation

Cancers, Journal Year: 2025, Volume and Issue: 17(7), P. 1237 - 1237

Published: April 5, 2025

Treatment of lung adenocarcinoma has changed and now includes checkpoint inhibitors (CPIs) or, in the case an EGFR mutation, third-generation TKI osimertinib. Few data compare long-term overall survival (OS) current historic subgroups. This real-world analysis (KOMPASS study) included stage IV lung-adenocarcinoma patients with either EGFR, KRAS, or no mutation. Patients were assigned to "current" no-mutation cohort if they had mutation testing using NGS (n = 199; median date diagnosis 2021). If PCR test only, "historic" 127; 2014). Both cohorts significantly longer OS than respective (HR 0.58 0.60, respectively). The a strong trend cohorts. In cohorts, improvement was due increase survivors 0.71), whereas improved without 0.70). KRAS showed like cohort, plateau around 20%. A comparison our that phase III trials KEYNOTE-189 FLAURA suggests outcomes are use CPIs clinical trial results well translated into practice comparable OS. benefit from CPI treatment patients.

Language: Английский